VistaGen Therapeutics Q3 EPS $(0.22) Beats $(0.30) Estimate, Sales $411.40K Miss $544.50K Estimate
VistaGen Therapeutics Q3 EPS $(0.22) Beats $(0.30) Estimate, Sales $411.40K Miss $544.50K Estimate
VistaGen Therapeutics第三季度每股收益美元（0.22美元）超過預期（0.30美元），銷售額爲411.4萬美元，低於預期的544.5萬美元
VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.30) by 26.67 percent. This is a 84.51 percent increase over losses of $(1.42) per share from the same period last year. The company reported quarterly sales of $411.40 thousand which missed the analyst consensus estimate of $544.50 thousand by 24.44 percent. This is a 129.06 percent increase over sales of $179.60 thousand the same period last year.
VistaGen Therapeutics（納斯達克股票代碼：VTGN）公佈的季度虧損爲每股0.22美元，比分析師共識估計的美元（0.30美元）高出26.67％。與去年同期每股虧損1.42美元（1.42）相比，增長了84.51％。該公司公佈的季度銷售額爲411,400美元，比分析師普遍預期的544,500美元低24.44％。這比去年同期的179,600美元的銷售額增長了129.06％。